Anti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitis
- 4 November 2011
- Vol. 67 (2), 183-190
- https://doi.org/10.1111/j.1398-9995.2011.02735.x
Abstract
To cite this article: Kim YH, Yang TY, Park C‐S, Ahn S‐H, Son BK, Kim JH, Lim DH, Jang TY. Anti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67: 183–190. Abstract Background: Interleukin (IL)‐33 is involved in the Th2 immune response and could play an essential role in nasal allergy. Therefore, we aimed to investigate the therapeutic potential of anti‐IL‐33 for allergic rhinitis (AR). Methods: Twenty‐four BALB/c mice were used. In group A (control group, n = 6), mice were sensitized and challenged with saline. Group B [ovalbumin (OVA) group, n = 6] mice received intraperitoneal and intranasal OVA challenge. In group C (control IgG group, n = 6), mice were injected intraperitoneally with rabbit control IgG before OVA challenge. In group D (anti‐IL‐33 group, n = 6), anti‐IL‐33 was injected before challenge. We evaluated the number of nose‐scratching events and external morphology; serum total and OVA‐specific IgE; number of eosinophils, neutrophils, and lymphocytes in bronchoalveolar lavage (BAL) fluid; histopathologic examination of nasal cavity; and IL‐4, IL‐5, and IL‐13 in BAL fluid. Results: Anti‐IL‐33 treatment significantly reduced the nose‐scratching events and ameliorated skin denudation. Serum total and OVA‐specific IgE was significantly decreased in group D. The number of eosinophils in BAL fluid was also significantly decreased. Eosinophilic infiltration in the nasal cavity was significantly decreased in group D. IL‐4, IL‐5, and IL‐13 in BAL fluid were also significantly decreased after treatment. Conclusions: Anti‐IL‐33 antibody has a therapeutic potential for experimental AR.Keywords
This publication has 26 references indexed in Scilit:
- IL-33 family members and asthma – bridging innate and adaptive immune responsesCurrent Opinion in Immunology, 2010
- RETRACTED: The cytokine interleukin-33 mediates anaphylactic shockProceedings of the National Academy of Sciences, 2009
- Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2–IL-33 PathwayAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33Blood, 2009
- The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’?PLOS ONE, 2008
- A novel IL-1 family cytokine, IL-33, potently activates human eosinophilsJournal of Allergy and Clinical Immunology, 2008
- Tissue Distribution and Subcellular Localization of a Variant Form of the Human ST2 Gene Product, ST2VBiochemical and Biophysical Research Communications, 2001
- The other side of the coin: The protective role of the TH2 cytokinesJournal of Allergy and Clinical Immunology, 2001
- Crucial Role of the Interleukin 1 Receptor Family Member T1/St2 in T Helper Cell Type 2–Mediated Lung Mucosal Immune ResponsesThe Journal of Experimental Medicine, 1999
- The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.The Journal of Experimental Medicine, 1992